Mobility devices co makes maiden Dx buy with 180º turntowards pharma and biotech strategy
This article was originally published in Clinica
Executive Summary
Heralding a complete U-turn in its strategic direction, mobility products company Modern Mobility Aids (MMA) has agreed to purchase Canadian molecular diagnostics specialist LumiGene Technologies. MMA will pay Can$1m ($1.02m) upfront for LumiGene, as well as 2% of all gross revenue realised from the business after the deal has closed and up to Can$480,000 in additional milestone payments.